Shares of Heat Biologics Inc (NASDAQ:HTBX) fell 4.3% during trading on Wednesday . The company traded as low as $1.32 and last traded at $1.32. 12,297 shares were traded during mid-day trading, a decline of 97% from the average session volume of 488,476 shares. The stock had previously closed at $1.38.
A number of research firms recently commented on HTBX. HC Wainwright set a $6.00 target price on shares of Heat Biologics and gave the stock a “buy” rating in a report on Friday, November 16th. ValuEngine upgraded shares of Heat Biologics from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.
Heat Biologics (NASDAQ:HTBX) last released its earnings results on Thursday, November 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.05. The business had revenue of $1.84 million for the quarter, compared to the consensus estimate of $1.50 million. Heat Biologics had a negative net margin of 331.02% and a negative return on equity of 94.53%. As a group, research analysts forecast that Heat Biologics Inc will post -1.1 EPS for the current year.
Heat Biologics Company Profile (NASDAQ:HTBX)
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.